Brandi Huffman
Physician Assistant · Princeton, WVNPI 1306935721
Payments from drug & device makers
Across 138 payments — averaging $14.75 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$645
- AbbVie$345
- AstraZeneca$314
- GSK$195
- Merck$121
- Pfizer$100
- plus $315 from 11 others
What the payments were for
- Food & beverage$2,035100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk | 41 | $645 |
| AbbVie | 29 | $345 |
| AstraZeneca | 20 | $314 |
| GSK | 16 | $195 |
| Merck | 8 | $121 |
| Pfizer | 6 | $100 |
| Novartis | 3 | $54 |
| Amgen | 3 | $48 |
| Boehringer Ingelheim | 2 | $31 |
| Abbott | 2 | $30 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 2 | $29 |
| Insulet Corporation | 1 | $25 |
| Biohaven Pharmaceutical Holding Company Ltd. | 1 | $24 |
| Dexcom, Inc. | 1 | $22 |
| Lilly USA, LLC | 1 | $20 |
| Idorsia Pharmaceuticals US Inc | 1 | $18 |
| Biogen | 1 | $13 |
How this compares
$2,035 in reported general payments places this provider in the 85th percentile of 833 physician assistant providers in West Virginia.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 106 | $155,249 |
| FarxigaDapagliflozin Propanediol | 78 | $82,556 |
| JardianceEmpagliflozin | 71 | $77,116 |
| TradjentaLinagliptin | 46 | $51,333 |
| JanuviaSitagliptin Phosphate | 53 | $47,776 |
| LinzessLinaclotide | 42 | $46,474 |
| EliquisApixaban | 35 | $44,643 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 41 | $33,516 |
| TrulicityDulaglutide | 15 | $25,875 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 88 | $18,920 |
| Tresiba Flextouch U-200Insulin Degludec | 16 | $18,498 |
| Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog | 41 | $17,527 |
| Novolog FlexpenInsulin Aspart | 45 | $15,087 |
| Humalog Kwikpen U-100Insulin Lispro | 12 | $3,481 |
| Famotidine | 215 | $3,161 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic | $645 | $155,249106 claims |
| Boehringer IngelheimJardiance, Tradjenta | $31 | $128,448117 claims |
| AstraZenecaFarxiga | $314 | $82,55678 claims |
| MerckJanuvia | $121 | $47,77653 claims |
| AbbVieLinzess | $345 | $46,47442 claims |
| PfizerEliquis | $100 | $44,64335 claims |
| GSKTrelegy Ellipta | $195 | $33,51641 claims |
| Lilly USA, LLCTrulicity | $20 | $25,87515 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 833 physician assistant providers in West Virginia.
Other physician assistant in Princeton
- Jennifer RiffePrinceton$9K
- Heather CookPrinceton$6K
- Erika PowellPrinceton$5K
- Amy ButtsWellsburg$258K
- Alexander EpperlySouth Charleston$21K
- Kelley WhoolerySouth Charleston$17K
- Jordan BrewerMorgantown$15K
- Tasha ElswickWinfield$14K
- Frances PauleyCharleston$14K
- Danielle MolinaCharleston$12K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.